Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Suspended 1Not yet recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Lymphoma, B-Cell 2Colorectal Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Platinum-resistant Ovarian Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Microsatellite Instability 1Melanoma 1Lung Neoplasms 1Liposarcoma, Myxoid 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 25Cisplatin 23Carboplatin 18Magnetic Resonance Spectroscopy 16Paclitaxel 15Specimen Handling 14Pemetrexed 11durvalumab 9Radiotherapy, Intensity-Modulated 8Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Nivolumab 7Radiation 6Docetaxel 6Cetuximab 6Biopsy 6osimertinib 5cemiplimab 5Taxes 5Radiotherapy 5Ipilimumab 5Cyclophosphamide 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5poly ICLC 4cabozantinib 4atezolizumab 4Oxaliplatin 4Gemcitabine 4Fluorouracil 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × ALT-803 × 1 year × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT07574541 2026-06-05

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Institutes of Health Clinical Center (CC)

Phase 2 Not yet recruiting
52 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡